-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $63

Benzinga·03/16/2026 12:29:56
Listen to the news
Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $64 to $63.